11/29
03:34 pm
apm
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:11 am
apm
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]
Low
Report
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]
11/19
08:00 am
apm
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
Low
Report
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
10/10
10:56 am
apm
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering [Yahoo! Finance]
Neutral
Report
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering [Yahoo! Finance]
10/10
09:54 am
apm
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
High
Report
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
10/9
08:55 am
apm
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
Low
Report
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
10/3
03:30 pm
apm
Aptorum Group (NASDAQ:APM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptorum Group (NASDAQ:APM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.